Friday, July 10, 2026

Drug profile · INN

amifostine

amifostine (ETHYOL) is a reactive metabolite scavenging agent. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — amifostine
US status
approved
Class
Route
INJECTION
Patents
0
Programs
2
Data quality
0.84

Quick answer

amifostine (ETHYOL) is a reactive metabolite scavenging agent. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN amifostine
Brand ETHYOL
Mechanism Reactive metabolite scavenging agent
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Reactive metabolite scavenging agent

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. GRA.05.SPR.0001 Phase 2 · Anaxis Pharma · Radiation-induced dermatitis (radiodermatitis)
  2. amifostine Phase 1 · Ultragenyx UK · Fanconi's Anemia

Frequently asked questions

What is amifostine?

amifostine (ETHYOL) is a reactive metabolite scavenging agent. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for amifostine?

ETHYOL is a marketed brand name for amifostine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of amifostine?

amifostine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.